Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zai Lab Limited before investing.

In this article, we go over a few key elements for understanding Zai Lab Limited’s stock price such as:

• Zai Lab Limited’s current stock price and volume
• Why Zai Lab Limited’s stock price changed recently
• Upgrades and downgrades for ZLAB from analysts
• ZLAB’s stock price momentum as measured by its relative strength

About Zai Lab Limited (ZLAB)

Before we jump into Zai Lab Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Want to learn more about Zai Lab Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zai Lab Limited.

What Caused Zai Lab Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 01, 2026, there were 2 analysts who downgraded Zai Lab Limited’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Zai Lab Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zai Lab Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Zai Lab Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zai Lab Limited (ZLAB) by visiting AAII Stock Evaluator.

Relative Price Strength of Zai Lab Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2026, Zai Lab Limited has a weighted four-quarter relative price strength of -2.60%, which translates to a Momentum Score of 46 and is considered to be Average.

Want to learn more about how Zai Lab Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zai Lab Limited Stock Price: Bottom Line

As of May 1, 2026, Zai Lab Limited’s stock price is $21.540, which is down 0.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zai Lab Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.